Huanliang Meng

Huanliang Meng

Auto-generated profile, based on publicly available information

Huanliang Meng

Shanghai Bone Tumor Institution, Shanghai, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JSJianguo Song
Jianguo Song
HMHuanliang Meng
Huanliang Meng
GDGuoying Deng
Guoying Deng
JSjianguo song
jianguo song
Background: Inhibiting ROS overproduction is considered a very effective strategy for the treatment of peripheral nerve injuries, and Se has a remarkable antioxidant effect; however, since the difference between the effective concentration of Se and the toxic dose is not large, we synthesized a nanomaterial that can release Se slowly so that it can be used more effectively. Methods: Se@SiO2 NPs were synthesized using a mixture of Cu2-x Se nanocrystals, and the mechanism of action of Se@SiO2 NPs was initially explored by performing sequencing, immunofluorescence staining and Western blotting of cellular experiments. The mechanism of action of Se@SiO2 NPs was further determined by performing behavioral assays after animal experiments and by sampling the material for histological staining, immunofluorescence staining, and ELISA. The effects, mechanisms and biocompatibility of Se@SiO2 NPs for peripheral nerve regeneration were determined. Results: Porous Se@SiO2 was successfully synthesized, had good particle properties, and could release Se slowly. CCK-8 experiments revealed that the optimal experimental doses were 100 μM H2O2 and 200 μg/mL Se@SiO2, and RNA-seq revealed that porous Se@SiO2 was associated with cell proliferation, apoptosis, and the PI3K/AKT pathway. WB showed that porous Se@SiO2 could increase the expression of cell proliferation antigens (PCNA and S100) and antiapoptotic proteins (Bcl-2), decrease the expression of proapoptotic proteins (Bax), and increase the expression of antioxidative stress proteins (Nrf2, HO-1, and SOD2). EdU cell proliferation and ROS fluorescence assays showed that porous Se@SiO2 promoted cell proliferation and reduced ROS levels. The therapeutic effect of LY294002 (a PI3K/AKT pathway inhibitor) was decreased significantly and its effect was lost when it was added simultaneously with porous Se@SiO2. Animal experiments revealed that the regenerated nerve fiber density, myelin thickness, axon area, gastrocnemius muscle wet-to-weight ratio, myofiber area, sciatic nerve function index (SFI), CMAP, apoptotic cell ratio, and levels of antioxidative stress proteins and anti-inflammatory factors were increased following the administration of porous Se@SiO2. The levels of oxidative stress proteins and anti-inflammatory factors were significantly greater in the Se@SiO2 group than in the PNI group, and the effect of LY294002 was decreased significantly and was lost when it was added simultaneously with porous Se@SiO2. Conclusion: Se@SiO2 NPs are promising, economical and effective Se-releasing nanomaterials that can effectively reduce ROS production, inhibit apoptosis and promote cell proliferation after nerve injury via the PI3K/AKT pathway, ultimately accelerating nerve regeneration. These findings could be used to design new, promising drugs for the treatment of peripheral nerve injury.

1 March 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
WZWeisong Zhao
Weisong Zhao
HMHuanliang Meng
Huanliang Meng
ZDZhenwu Dai
Zhenwu Dai
LZLulu Zhang
Lulu Zhang
ZCZhiwei Cheng
Zhiwei Cheng
YHYingqi Hua
Yingqi Hua
PURPOSE: Osteosarcoma (OS) is the most prevalent primary malignant bone sarcoma, characterized by its high rates of metastasis and mortality. In our previous multiomics analysis of the Shanghai General Hospital OS (SGH-OS) cohort, we identified four distinct OS subtypes, each with unique molecular characteristics and clinical outcomes. Of particular importance was the identification of the MYC-driven subtype, which exhibited the poorest prognosis and was referred to as high-risk OS. A diagnostic tool is needed for clinicians to identify high-risk OS in advance. The purpose of this study is to develop a classifier capable of accurately predicting the high-risk OS subtype using transcriptome and methylation data. METHODS: In this study, using eXtreme Gradient Boosting (XGBoost) with Bayesian optimization, we developed a classification model by integrating transcriptome and methylation data from our internal SGH-OS cohort. We further validated the model's predictive performance with the external TARGET-OS cohort. RESULTS: Using the XGBoost algorithm, we developed a classifier incorporating nine genes (ARHGAP9, CADM1, CPE, DUSP3, FGFR1, GALNT3, IGF2BP3, KIF26A, ZFP3). In our internal cohort, the classifier exhibited excellent predictive performance, with an area under the receiver operating characteristics curve (AUC) of 0.999 and an overall accuracy of 0.989. Furthermore, the classifier successfully stratified two groups with distinct survival outcomes in the external TARGET-OS cohort. Notably, our analysis revealed a positive correlation between IGF2BP3 and MYC signaling pathways, highlighting IGF2BP3 as a potential therapeutic target in high-risk OS. CONCLUSION: Our classifier demonstrated excellent predictive performance in identifying patients with high-risk OS, offering the potential to enhance treatment decision making and optimize patient management strategies.

5 June 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
LYLingfeng Yu
Lingfeng Yu
MLMengpan Li
Mengpan Li
TLTongtong Liu
Tongtong Liu
JWJiangpeng Wu
Jiangpeng Wu
HMHuanliang Meng
Huanliang Meng
ZCZhengdong Cai
Zhengdong Cai
Osteosarcoma responds poorly to immune-checkpoint blockade (ICB), and the molecular drivers of its immune-cold state remain unclear. Using multi-omics analyses, we identified an immune-cold osteosarcoma subtype characterized by enrichment of protein SUMOylation and found the SUMO E1 subunit UBA2 as a key driver. UBA2 was anomalously upregulated in osteosarcoma cohorts and linked to worse outcomes. Functionally, UBA2 promoted autophagy, thereby exerting noncanonical protumor and immunosuppressive effects. Mechanistically, UBA2 catalyzed SUMO2-dependent SUMOylation of SESN2, enhancing autophagic flux. At the immune interface, UBA2 did not alter the expression of immune checkpoint molecules but reduced surface MHC-I through NBR1-mediated autophagy–lysosomal degradation, thereby limiting CD8+ T-cell infiltration. In vivo, pharmacologic UBA2 inhibition with ML-792 slowed tumor growth and sensitized tumors to ICB therapy. Together, these findings show that UBA2 links SUMOylation to autophagy-driven loss of antigen presentation and immune exclusion, highlighting the UBA2–autophagy–MHC-I axis as a therapeutic target and potential biomarker in osteosarcoma.

2 July 2026
Verified
Other
Open access
LYLingfeng Yu
Lingfeng Yu
MLMengpan Li
Mengpan Li
TLTongtong Liu
Tongtong Liu
JWJiangpeng Wu
Jiangpeng Wu
HMHuanliang Meng
Huanliang Meng
ZCZhengdong Cai
Zhengdong Cai
Supplementary Figure S3: Single-cell transcriptomic quality control, batch effect correction, clustering, and cell-type annotation.

2 July 2026
Verified
Other
Open access
PDF file
LYLingfeng Yu
Lingfeng Yu
MLMengpan Li
Mengpan Li
TLTongtong Liu
Tongtong Liu
JWJiangpeng Wu
Jiangpeng Wu
HMHuanliang Meng
Huanliang Meng
ZCZhengdong Cai
Zhengdong Cai
Supplementary Table S3. Omics cohort.

2 July 2026
Verified
Other
Open access
LYLingfeng Yu
Lingfeng Yu
MLMengpan Li
Mengpan Li
TLTongtong Liu
Tongtong Liu
JWJiangpeng Wu
Jiangpeng Wu
HMHuanliang Meng
Huanliang Meng
ZCZhengdong Cai
Zhengdong Cai
Supplementary Figure S8. UBA2 drives OS malignant phenotypes and impairs T-Cell cytotoxicity in vitro.